Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer
Status:
Recruiting
Trial end date:
2025-02-14
Target enrollment:
Participant gender:
Summary
This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy
Followed by Adjuvant Durvalumab or Placebo in Patients with Resectable Gastric and
Gastroesophageal Cancer (GC/GEJC) (MATTERHORN).